PT  - JOURNAL ARTICLE
AU  - Abdalla Akef
AU  - Kathy McGraw
AU  - Steven D. Cappell
AU  - Daniel R. Larson
TI  - Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation
AID  - 10.1101/2019.12.13.876284
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2019.12.13.876284
4099  - http://biorxiv.org/content/early/2020/03/25/2019.12.13.876284.short
4100  - http://biorxiv.org/content/early/2020/03/25/2019.12.13.876284.full
AB  - U2AF1 forms a heterodimeric complex with U2AF2 that is primarily responsible for 3’ splice site selection. U2AF1 mutations have been identified in most cancers but are prevalent in Myelodysplastic Syndrome and Acute Myeloid Leukemia, and the most common mutation is a missense substitution of serine-34 to phenylalanine (S34F). However, the U2AF heterodimer also has a non-canonical function as a translational regulator. Here, we report that the U2AF1 S34F mutation results in specific mis-regulation of the translation initiation and ribosome biogenesis machinery, with the potential for widespread translational changes. The net result is a global increase in mRNA translation at the single cell level. Among the translationally upregulated targets of U2AF1-S34F are Nucleophosmin1 (NPM1), which is a major driver of myeloid malignancy. Depletion of NPM1 impairs the viability of wt/S34F cells and causes rRNA processing defects, thus indicating an unanticipated synthetic interaction between U2AF1, NPM1 and ribosome biogenesis. Our results establish a unique molecular phenotype for the U2AF1 mutation which recapitulates translational mis-regulation in myeloid disease.